To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
daclizumab
|
| kidney transplantation - Zenapax (New drug) 23(1) 21 |
|
dacryocystitis
|
| management 17(3) 66-8 |
|
Daivonex
|
| see calcipotriol 25(2) 44-7; 24(6) 155-8 |
|
dalfopristin/quinupristin
|
| authority prescription applications (PBAC question) 22(2) 36 |
| Synercid IV (New drug) 23(3) 64-7 |
| in thromboembolism 19(4) 104-8 |
|
danaparoid
|
| in thromboembolism 19(4) 104-8 |
| thromboembolism - Orgaran (New drug) 17(3) 73 |
|
darbepoetin
|
| chronic renal failure - Aranesp (New drug) 25(1) 20-3 |
|
darifenacin hydrobromide
|
| Enablex - overactive bladder (New drug) 29(5) 138-43 |
|
darunavir
|
| Prezista - HIV infection (New drug) 30(3) 79-82 |
|
dasatinib
|
| Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-55 |
|
daunorubicin, liposomal
|
| Kaposi's sarcoma - DaunoXome (New drug) 21(3) 80-3 |
|
DaunoXome
|
| see daunorubicin 21(3) 80-3 |
|
DBL amoxycillin
|
| see amoxycillin trihydrate 23(3) 64-7 |
|
DBL atenolol
|
| see atenolol 22(6) 147-51 |
|
DBL cefotaxime
|
| see cefotaxime 24(6) 155-8 |
|
DBL clomipramine
|
| see clomipramine 23(2) 45-6 |
|
DBL diltiazem
|
| see diltiazem 23(2) 45-6 |
|
DBL gemfibrozil
|
| see gemfibrozil 23(2) 45-6 |
|
DBL ipratropium
|
| see ipratropium bromide 25(6) 147-51 |
|
DBL moclobemide
|
| see moclobemide 23(2) 45-6 |
|
DBL prazosin
|
| see prazosin hydrochloride 23(2) 45-6 |
|
DBL sotalol
|
| see sotalol 22(6) 147-51 |
|
deafness
|
| newborn hearing screening 26(4) 82-4 |
| patient support organisations 26(4) 87 |
|
deathcap mushrooms
|
| poisoning 23(2) 29 |
|
debridement
|
| of wounds 19(1) 11-3 |
| letter 19(3) 59-62 |
|
decision-making
|
| clinical intuition 25(1) 14-5 |
|
decision-support software - see electronic prescribing
|
|
decongestants
|
| in over-the-counter medication 24(6) 149-51 |
| letter 25(2) 27-8 |
| in sinusitis 23(2) 39-42 |
|
deep venous thrombosis - see thromboembolism
|
|
deferasirox
|
| Exjade - iron overload (New drug) 29(4) 112-5 |
|
deferiprone
|
| thalassaemia - Ferriprox (New drug) 26(3) 68-71 |
|
defibrillation
|
| management of cardiac arrest 20(2) 41-5 |
| PBAC question 20(4) 86-7 |
|
Definity
|
| see perflutren 30(4) 107-11 |
|
dehydration
|
| oral rehydration in childhood gastroenteritis (letter) 17(1) 4-5 |
|
delarvidine mesylate
|
| HIV - Rescriptor (New drug) 21(2) 49-55 |
|
Deltazine
|
| see articaine 28(1) 19-23 |
|
dementia
|
| donepezil - Alzheimer's disease (editorial) 28(6) 134-5 |
| donepezil - Alzheimers disease - Aricept (New drug) 22(1) 20-3 |
| management of behavioural problems 28(3) 67-70 |
| mental status testing 28(1) 11-3 |
| patient support organisations 28(3) 72; 19(1) 17 |
| positron emission tomography 18(1) 15-8 |
| risperidone for behavioural disturbances (RADAR comment) 28(3) 71 |
| tacrine - Alzheimers disease - Cognex (new formulation) 18(2) 35-8 |
| tacrine in Alzheimers disease 19(1) 14-7 |
|
dental anaesthesia
|
| articaine with adrenaline - Septanest, Deltazine, Bucanest (New drug) 28(1) 19-23 |
|
dental implications - see dental notes
|
|
dental notes
|
| adverse reaction reporting 28(6) 142 |
| antibiotics for surgical prophylaxis 28(2) 41 |
| letters 28(5) 113-5; 28(3) 55-8 |
| antineoplastics 18(3) 68 |
| letter - Oralmat Drops for oral pain relief 19(2) 36-8 |
| antiretroviral therapy in HIV infection 28(6) 149 |
| bioequivalence of generic drugs 30(2) 43 |
| breast cancer drug treatments 21(1) 27 |
| cancer chemotherapy in the aged 23(4) 83 |
| clinical investigations and professional indemnity 19(4) 97 |
| clinical investigations and professional negligence 19(4) 97 |
| consumer information 25(4) 90; 19(4) 97; 18(1) 12 |
| corticosteroids in dermatology and rheumatology 21(1) 27 |
| cytotoxic therapy, complications 18(3) 68 |
| digoxin in congestive heart failure 22(6) 144 |
| drug allergy 17(3) 65 |
| letter - latex allergy 18(1) 4-7 |
| drug promotion and dentistry 30(6) 153 |
| emergency drugs in dentistry 30(6) 146 |
| haemostasis disorders 18(2) 48 |
| hepatitis B 21(3) 79 |
| herpes simplex infections 30(1) 13 |
| influenza vaccination for healthy adults 30(2) 37 |
| management of hepatitis C 29(2) 52 |
| letter 30(3) 59-63 |
| management of post myocardial infarct patients 19(1) 13 |
| letter - warfarin potentiation and interactions 19(3) 59-62 |
| managing painful paediatric procedures 29(4) 108 |
| myasthenia gravis 30(6) 160 |
| neuropathic pain, drug treatment 29(3) 82 |
| postoperative analgesia 18(4) 87 |
| respiratory function tests 23(1) 21 |
| sinusitis 23(2) 43 |
| treatment of deep vein thrombosis 21(3) 79 |
| letter 22(1) 3-5 |
| warfarin and dental patients 25(3) 69 |
| letters 27(1) 3; 26(4) 75-7; 25(5) 104-7 |
| xerostomia 29(4) 108 |
|
dental pain
|
| emergency management 24(6) 144-8 |
| management 30(3) 77-9 |
|
dental surgery
|
| anticoagulation 23(1) 13-6 |
|
dentifrices
|
| safety 17(2) 49-51 |
|
dentistry
|
| antibiotic resistance 22(2) 26-8 |
| antiepileptics 17(1) 12 |
| bisphosphonates |
| and avascular necrosis of the jaw (letter) 27(2) 28-33 |
| and osteonecrosis of the jaws 30(4) 96-7 |
| dizziness and prolonged dental treatment (letter) 28(6) 136-9 |
| drug distribution in human milk 20(2) 35-40 |
| drug-induced gingival enlargement 26(1) 11-3 |
| drugs and gingival bleeding 29(6) 154-5 |
| echocardiography and endocarditis (letter) 30(1) 3-4 |
| endocarditis prophylaxis (letters) 21(4) 87-91; 21(2) 31-4 |
| gingival hyperplasia and nifedipine (letter) 17(1) 4-5 |
| periodontitis and diabetes 27(2) 36-8 |
| and psychotropic drugs 30(4) 98-101 |
| Therapeutic Guidelines - Oral and Dental (book review) 30(4) 106 |
|
deoxyribonuclease
|
| dornase alfa - Pulmozyme (New drug) 18(2) 35-8 |
|
depot formulations
|
| progestogen-only contraceptives 22(1) 6-8 |
|
depression (see also antidepressant drugs)
|
| antidepressants and suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3 |
| letter 29(2) 32-5 |
| antidepressants in pregnancy and breastfeeding 30(5) 125-7 |
| cognitive behaviour therapy 24(2) 33-7 |
| management in old age 24(3) 65-7 |
| management in young people 21(1) 20-2 |
| NHMRC guidelines (letter) 21(4) 87-91 |
| management of mild depression in general practice 28(1) 8-10 |
| in medical illness 30(4) 86-8 |
| new antidepressants 22(5) 106-8; 22(5) 108-11 |
| letter 22(6) 131-2 |
| overdoses and tricyclic antidepressants (letter) 17(2) 28-9 |
| stopping treatment and withdrawal symptoms 24(1) 13-5 |
| letter 24(3) 51-5 |
|
dermatitis
|
| diagnosis and management of vulvovaginitis in childhood 28(4) 88-90 |
| mometasone - Elocon (New drug) 17(1) 6-8 |
|
dermatitis, atopic
|
| pimecrolimus - Elidel (New drug) 26(6) 146-51 |
| letter 27(2) 28-33 |
|
dermatology
|
| dental implications 21(1) 27 |
| desonide - Desowen (New drug) 24(4) 100-2 |
| Therapeutic Guidelines (book review) 28(2) 44 |
| topical and systemic corticosteroids 21(1) 9-11 |
| letter 21(4) 87-91 |
| vulvovaginitis management 24(3) 59-61 |
|
dermatomycosis
|
| antifungal drugs 19(3) 72-5 |
|
dermatophytosis
|
| antifungal drugs 19(3) 72-5 |
| terbinafine and fungal toenails (PBAC question) 22(6) 135 |
| letter 23(4) 72 |
|
desensitisation
|
| allergy immunotherapy 26(4) 91-3 |
|
desferrioxamine mesylate
|
| New strength 23(6) 137-9 |
|
desirudin
|
| thromboembolism - Revasc (New drug) 23(6) 137-9 |
|
desmopressin acetate
|
| Minirin (New formulation) 26(5) 118-9 |
| new strength - Octostim 19(2) 38-40 |
|
desogestrel
|
| risk of thromboembolism 25(3) 57-9 |
|
desonide
|
| dermatoses - Desowen (New drug) 24(4) 100-2 |
|
Desowen
|
| see desonide 24(4) 100-2 |
|
Detrusitol
|
| see tolterodine 28(2) 49-51 |
|
developing countries
|
| cost of drugs (editorial) 26(2) 26-7 |
| expensive new drugs (editorials) 27(6) 136-7; 27(6) 137-8 |
|
dexamethasone
|
| in autoimmune disease 22(1) 9-11 |
| in croup 20(4) 99-101 |
|
dexamphetamine
|
| in attention deficit hyperactivity disorder 18(3) 60-3 |
| letters 19(3) 59-62; 19(2) 36-8; 19(1) 3-6 |
|
dexfenfluramine
|
| in obesity 22(1) 12-6 |
|
dexmedetomidine
|
| sedation - Precedex (New drug) 24(5) 129-31 |
|
dextromethorphan
|
| precipitating serotonin syndrome 29(3) 71 |
| letter 29(6) 149-50 |
|
diabetes
|
| acarbose - Glucobay (New drug) 21(2) 49-55 |
| anticonvulsants in neuropathic pain 22(6) 140-1 |
| anticonvulsants in neuropathic pain (letter) 23(4) 72 |
| antipsychotic drugs and risk of diabetes 27(5) 118-9 |
| costs of intensive management (editorial) 25(5) 102-3 |
| letter 26(1) 3-4 |
| deep vein thrombosis 21(3) 76-9 |
| letter 22(2) 28-31 |
| DNA tests - approach and techniques 18(2) 45-8 |
| DNA tests - clinical applications 18(3) 76-9 |
| letter - test for von Hippel Lindau syndrome 19(1) 3-6 |
| drug allergy 17(3) 62-5 |
| letter - vaccines and egg protein allergy 18(2) 27-9 |
| drug interactions with oral hypoglycaemic drugs 24(4) 83-5 |
| exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7 |
| exercise 30(5) 130-3 |
| letter 31(1) 3-4 |
| expensive medical technology (editorial) 17(3) 54-5 |
| letters 18(2) 27-9 |
| foot infections 30(1) 21-4 |
| foot ulcers - management 23(1) 6-9 |
| glimepiride - type 2 diabetes - Amaryl (New drug) 24(3) 71-5 |
| glucose 50% vs glucagon in doctor's bag supplies (PBAC question) 20(2) 33-4 |
| hyperlipidaemia 22(3) 67-9 |
| hypertension 25(1) 8-10 |
| letter 25(3) 51-3 |
| insulin analogues and delivery systems 25(2) 29-31 |
| letter 25(5) 104-7 |
| insulin aspart - NovoRapid (New drug) 24(1) 20-3 |
| insulin delivery devices 25(6) 136-8 |
| insulin detemir - Levemir FlexPen (New drug) 28(5) 130-1 |
| insulin glargine - Lantus (New drug) 27(2) 50-1 |
| letter 27(6) 138-41 |
| insulin glulisine - Apidra SoloStar (New drug) 30(5) 133-5 |
| insulin therapy and hypoglycaemic drugs 27(4) 93-6 |
| management of type 2 diabetes 20(3) 65-7 |
| metformin in pregnancy and lactation 30(3) 68-9 |
| overseas travel and insulin 29(3) 80-2 |
| patient support organisations 27(4) 96-7; 25(1) 10-1; 22(3) 69-70 |
| and periodontitis 27(2) 36-8 |
| pioglitazone - type 2 diabetes - Actos (New drug) 25(1) 20-3 |
| positron emission tomography in cardiology 18(1) 13-5 |
| positron emission tomography in neurology 18(1) 15-8 |
| pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9 |
| professional indemnity (editorial) 19(4) 86-7 |
| professional negligence (editorial) 19(4) 86-7 |
| repaglinide - type 2 diabetes - NovoNorm (New drug) 23(4) 84-7 |
| respiratory function - spirometry 23(1) 10-2 |
| rosiglitazone - Avandia (New drug) 24(1) 20-3 |
| sleep studies 21(2) 40-3 |
| letter 22(1) 3-5 |
| thallium scanning in coronary disease 17(3) 57-61 |
| thiazolidinedione pharmacology 27(3) 67-70; 27(3) 70-4 |
| troglitazone - Rezulin (New drug) 22(6) 147-51 |
| dental implications 23(1) 21 |
|
diabetes, gestational
|
| metformin in pregnancy and lactation 30(3) 68-9 |
|
Diabex
|
| see metformin 25(4) 94-9 |
|
diagnostic tests (see also abnormal laboratory results)
|
| cerebrovascular imaging (editorial) 24(6) 134 |
| magnetic resonance angiography 24(6) 137-40; 24(6) 141-3 |
| ultrasound 24(6) 137-40 |
| drug screens 24(4) 90-1 |
| echocardiography 29(5) 134-8 |
| letter 30(1) 3-4 |
| gluten enteropathy 24(2) 38-40 |
| likelihood ratios and interpretation 26(5) 111-13 |
| magnetic resonance imaging in neuroradiology 31(1) 18-20 |
| mental status testing in dementia 28(1) 11-3 |
| newborn hearing screening 26(4) 82-4 |
| oximetry 26(6) 132-5 |
| nail polish removal (letter) 27(2) 28-33 |
| recurrent deep venous thrombosis 30(2) 38-40 |
| sensitivity and specificity 26(5) 111-13; 25(5) 107 |
| letter 25(6) 131-2 |
| thyrotropin alfa-rch - thyroid cancer diagnosis - Thyrogen (New drug) 24(6) 155-8 |
|
Diamicron
|
| see gliclazide 24(6) 155-8 |
|
diarrhoea
|
| coeliac disease diagnosis (letter) 25(2) 27-8 |
| irritable bowel syndrome - management 24(3) 68-71 |
| oral rehydration in children (letter) 17(1) 4-5 |
|
Diavonex
|
| see calcipotriol 22(1) 20-3 |
|
diazepam
|
| convulsions in children 21(2) 35-6 |
|
diclofenac sodium
|
| Clonac (New brand) 27(1) 21-3 |
| Dinac (New brand) 22(6) 147-51 |
| hepatotoxicity (letter) 19(4) 92-3 |
| new formulation - potassium salt - Voltaren 17(1) 6-8 |
|
Diclosig
|
| see dicloxacillin 22(5) 125-7 |
|
dicloxacillin
|
| alternative to flucloxacillin - Distaph (New drug) 21(1) 25-7 |
| Diclosig (New brand) 22(5) 125-7 |
| warfarin interactions (letter) 21(3) 60-3 |
|
didanosine
|
| Videx EC (New formulation) 24(4) 100-2 |
|
dienogest/ethinyloestradiol
|
| Valette - contraceptive (New drug) 30(2) 50-55 |
|
diet
|
| antioxidants and nutrition 22(6) 142-4 |
| calcium 26(6) 126-7 |
| management of childhood obesity 26(2) 30-2 |
| management of obesity 29(2) 43-7 |
| management of undernutrition 24(5) 113-5 |
| nutrition and surgical outcomes 26(6) 136-40 |
| in obesity 22(1) 12-6 |
| in renal calculi 19(4) 94-7 |
|
Differin
|
| see adapalene 20(2) 45-51 |
|
digoxin
|
| in atrial fibrillation 23(5) 100-2 |
| brands and dosages 29(6) 153 |
| letter 30(2) 32-4 |
| in congestive heart failure 22(6) 136-7 |
| dental implications 22(6) 144 |
| in doctor's bag supplies (PBAC question) 20(4) 86-7 |
| in heart failure 23(6) 118-20; 23(6) 120-3 |
| letter 23(3) 55-6 |
| vs pethidine in migraine 20(3) 71 |
|
dihydropyridines
|
| clinical pharmacology of calcium channel antagonists 20(1) 5-8 |
| lercanidipine - Zanidip (New drug) 24(6) 155-8 |
| nifedipine and gingival hyperplasia (letter) 17(1) 4-5 |
| and nocturia, urination 20(1) 3-4 |
| and risk of myocardial infarction (editorial) 22(1) 2-3; 19(2) 35 |
|
Dilatrend
|
| see carvedilol 21(3) 80-3 |
|
Dilaudid
|
| see hydromorphone 23(4) 84-7 |
|
diltiazem
|
| Cardizem (New formulation) 23(5) 110-1 |
| Cardizem (New strength) 24(1) 20-3 |
| clinical pharmacology of calcium channel antagonists 20(1) 5-8 |
| DBL diltiazem (New brand) 23(2) 45-6 |
| new brand - Dilzem 18(1) 7-9 |
|
Dilzem
|
| see diltiazem 18(1) 7-9 |
|
Dimetriose
|
| see gestrinone 19(1) 24-7 |
|
Dinac
|
| see diclofenac 22(6) 147-51 |
|
DIPEx
|
| patient experiences website - review 25(4) 93-4 |
|
diphtheria, tetanus and pertussis vaccine
|
| diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65 |
| see triple antigen 24(4) 100-2 |
|
dipyridamole
|
| aspirin - Asantin SR (New combination) 23(3) 64-7 |
| Persantin SR (New formulation) 22(5) 125-7 |
| warfarin interactions 25(4) 81-5 |
|
disabilities, intellectual
|
| Therapeutic Guidelines 22(4) 88-90 |
|
discharge medication
|
| information and prescriptions (editorial) 29(3) 58-9 |
| letters 29(5) 121 |
|
disease outbreaks
|
| antiviral drugs and influenza prophylaxis 30(2) 30-1 |
| pandemic preparedness and antiviral drugs (letter) 25(3) 51-3 |
|
disodium cromoglycate
|
| see sodium cromoglycate 18(1) 12 |
| Vasocardol CD (New brand) 22(6) 147-51 |
|
disodium gadoxetate
|
| Primovist - liver imaging (New drug) 29(3) 84-7 |
|
disodium pamidronate
|
| and breast disease - letter 22(2) 28-31 |
| osteoporosis 23(6) 133-6 |
|
Distaph
|
| see dicloxacillin 21(3) 60-3; 21(1) 25-7 |
|
disulfiram
|
| alcohol dependence 25(3) 70-3 |
|
diuresis
|
| clinical pharmacology of calcium channel antagonists 20(1) 5-8 |
| dihydropyridines and nocturia 20(1) 3-4 |
|
diuretics
|
| and ACE inhibitors in heart failure (editorial) 19(1) 2-3 |
| drug-induced hyponatraemia 26(5) 114-7 |
| letters 27(2) 28-33 |
| in hypertension (editorial) 22(5) 102-3 |
| in renal calculi 19(4) 94-7 |
| thiazide diuretics and osteoporosis 24(3) 65-7 |
| vs ACE inhibitors in hypertension 27(4) 98-101 |
|
Divina
|
| see oestradiol medroxyprogesterone combination 18(3) 58-9 |
|
dizziness
|
| diagnosis and management 28(4) 94-7 |
| dental treatment (letter) 28(6) 136-9 |
|
DMPA
|
| see medroxyprogesterone 22(1) 6-8 |
|
DNA tests
|
| approach and techniques 18(2) 45-8 |
| clinical applications 18(3) 76-9 |
| letter - test for von Hippel Lindau syndrome 19(1) 3-6 |
| gene therapy 20(3) 72-3 |
|
dobutamine
|
| new brand - dobutamine hydrochloride injection 17(2) 30-2 |
|
docetaxel
|
| breast and lung cancer - Taxotere (New drug) 19(2) 38-40 |
| breast cancer (PBAC question) 30(1) 24-5 |
| doctor shoppers 20(3) 68-70 |
|
doctor's bag
|
| see emergency supplies 30(6) 143-6 |
|
dolasetron mesylate
|
| antiemetic - Anzemet (New drug) 20(4) 101-3 |
|
domiciliary services
|
| chronic obstructive pulmonary disease 30(3) 64-7 |
| hospital in the home 20(4) 88-9 |
| hospital in the home - book review 26(4) 93 |
| oxygen therapy 19(3) 69-71 |
|
donepezil
|
| Alzheimer's disease (editorial) 28(6) 134-5 |
| letter 29(3) 59-62 |
| Alzheimer's disease - Aricept (New drug) 22(1) 20-3 |
|
dopamine
|
| clinical pharmacology - cardiovascular 17(2) 44-5 |
| clinical pharmacology - psychiatry 17(2) 44-5 |
| pharmacology 17(1) 17-21 |
| pharmacology - Parkinson's disease 17(1) 17-21 |
|
dopamine agonists
|
| cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21 |
| in Parkinson's disease 24(4) 92-5 |
| quinagolide - hyperprolactinaemia - Norprolac (New drug) 28(6) 156-8 |
|
dopamine receptors
|
| clinical pharmacology - cardiovascular 17(2) 44-5 |
| pharmacology 17(1) 17-21 |
|
dopexamine
|
| dopamine cardiovascular pharmacology 17(2) 44-5 |
|
dornase alfa
|
| cystic fibrosis - Pulmozyme (New drug) 18(2) 35-8 |
| dorzolamide - glaucoma - Trusopt Eye Drops (New drug) 20(2) 45-51 |
|
dorzolamide
|
| in glaucoma 25(6) 142-6 |
| timolol - Cosopt (New combination) 25(4) 94-9 |
|
dose regimens
|
| pharmacokinetics 19(3) 76-8 |
| therapeutic drug monitoring 20(1) 9-11 |
| letters 20(3) 57-60 |
|
dose response relationship
|
| pharmacokinetics 18(4) 102-4 |
|
dosing
|
| missed doses 25(1) 16-8 |
| letter 25(3) 51-3 |
| splitting tablets 25(6) 133-5 |
| letters 26(2) 27-9 |
|
Dostinex
|
| doxazocin - antihypertensive - Carduran (New drug) 18(4) 86-7 |
| see cabergoline 19(1) 24-7 |
|
Dotarem
|
| see gadoteric acid 25(6) 147-51 |
|
Down's syndrome
|
| biochemical tests in pregnancy 29(2) 48-52 |
|
doxazosin
|
| doxorubicin cardiotoxicity and radiotherapy (letter) 19(2) 36-8 |
| in hypertension (letter) 23(6) 115-7 |
|
Doxy-50
|
| see doxycycline 25(6) 147-51 |
|
doxycycline
|
| Doxy-50 Acne Pack (New brand) 25(6) 147-51 |
| Doxyhexal (New brand) 22(5) 125-7 |
| dressings for wounds 23(1) 6-9; 19(1) 11-3 |
| in lower respiratory tract infections 19(2) 48-51 |
| malaria and travel 25(3) 66-9 |
| in malaria prophylaxis (letter) 17(3) 55-6 |
|
drospirenone/ethinyloestradiol
|
| contraceptive - Yasmin (New drug) 25(6) 147-51 |
|
drotrecogin alfa
|
| sepsis - Xigris (New drug) 25(6) 147-51 |
|
drug abuse
|
| doping in sport (editorial) 17(4) 78-9 |
| letters 18(3) 56-7 |
| drug screens 24(4) 90-1 |
| 'Drugs of abuse' (book review) 29(1) 8 |
| drug-seeking behaviour 20(3) 68-70 |
| dental implications 20(3) 61-4 |
| naltrexone - ReVia (New drug) 22(2) 43-7 |
| letter 22(5) 103-5 |
| needle-stick injuries 24(4) 98-100 |
| postoperative pain management in drug dependent patients 18(4) 88-91 |
| psychostimulant poisoning 29(4) 109-11 |
|
drug allergy
|
| pertussis vaccination (letter) 18(3) 56-7 |
| testing 17(3) 62-5 |
| dental implications 17(3) 65 |
|
drug bioavailability
|
| PBAC question 23(5) 99 |
|
drug bulletins - see drug information
|
|
drug costs - see cost of drugs
|
|
drug dependence
|
| buprenorphine - opiate dependence - Subutex (New drug) 24(3) 71-5 |
| correction 24(5) 129-31 |
| bupropion - nicotine dependence - Zyban (New drug) 24(1) 20-3 |
| drug treatment for opioid dependence 24(1) 4-6 |
| letter 24(3) 51-5 |
| drug-seeking behaviour 20(3) 68-70 |
| dental implications 20(3) 61-4 |
| pethidine in migraine 20(3) 71 |
| letter 21(2) 31-4 |
| temazepam capsules and injecting drug users 27(3) 58-9 |
| letter 27(5) 109-13 |
|
drug evaluation
|
| appraising medical research 29(5) 122-4 |
| Australian and Ontario policies 25(6) 128-30 |
| Australian drug regulatory system 18(3) 69-71 |
| price of drugs and developing countries (letter) 19(1) 3-6 |
| Australian Prescriber New drugs section editorial policy 25(5) 120-3 |
| development of new prescription drugs 29(6) 159-61 |
| drug availability in Australia: the Baume report (editorial) 18(3) 69-71 |
| economic analysis and the drug industry (editorial) 25(6) 126-7 |
| economic analysis and the drug industry (editorials) 22(3) 50-1 |
| freedom of publication (editorial) 29(5) 120 |
| letter 30(2) 32-4 |
| interpretation of clinical trials 23(2) 38; 20(4) 93-6; 20(3) 61-4 |
| letters 24(3) 51-5; 23(6) 115-7 |
| interpreting risks and ratios in clinical trials 31(1) 12-6 |
| product information 18(1) 19-21; 17(2) 39-41 |
| and medical journals (letter) 17(1) 4-5 |
| secrecy of drug regulatory information (editorial) 25(4) 78-9 |
| comments 25(5) 103-4 |
| Therapeutic Goods Administration approval processes 27(6) 156-8 |
| transparency of information about new drugs |
| editorial 28(4) 83-4 |
| transparency rating 30(1) 26-7; 28(4) 103 |
| letter 29(3) 59-62 |
|
drug industry (see also advertising)
|
| 1907 Royal Commission on Secret Drugs, Cures and Foods 30(4) 91 |
| advertising Code of conduct 22(4) 78-80 |
| advertising codes and consumers (editorial) 22(4) 74-5 |
| Australian Prescriber - editorial independence 17(4) 82-4 |
| chiral drugs 27(2) 47-9 |
| correction 28(3) 55-8 |
| letter 27(5) 109-13 |
| confusing drug brand names (letter) 17(4) 79-81 |
| cost of drugs and drug industry profits (editorial) 26(2) 26-7 |
| letter 26(3) 51-2 |
| development of new prescription drugs 29(6) 159-61 |
| direct-to-consumer advertising 27(1) 4-6 |
| in New Zealand (editorial) 29(2) 30-2 |
| discontinuation of naproxen suspension (letter) 25(5) 104-7 |
| drug promotion and health professionals 30(6) 150-3 |
| economic analysis and drug evaluation (editorials) 22(3) 50-1 |
| effectiveness of new drugs (editorial) 27(1) 2-3 |
| letter 27(3) 55-7 |
| expensive new drugs (editorials) 27(6) 136-7; 27(6) 137-8 |
| letter 28(3) 55-8 |
| gabapentin promotion and off-label prescribing 26(1) 18-9 |
| editorial comment 26(1) 19 |
| letters 27(4) 82-3; 26(3) 51-2; 26(2) 27-9 |
| generic drug marketing 26(4) 85-7 |
| letters 26(6) 124-5 |
| and the media (editorial) 23(4) 70-1 |
| Medicines Australia |
| code of conduct breaches 30(6) 153-5; 29(6) 164-5; 29(1) 16-7; 27(6) 141; 27(3) 60; 27(1) 6-7; 26(3) 66; 26(3) 67 |
| vardenafil 30(6) 154 |
| declarations of interest (letter) 26(5) 99-102 |
| 'Medicines out of control?' (book review) 27(5) 117 |
| patent evergreening (editorial) 29(6) 148-9 |
| 'Powerful medicines' (book review) 28(4) 101 |
| product discontinuations (editorial) 26(3) 50-1; 22(6) 138-9 |
| letters 26(5) 99-102 |
| product information 19(2) 30-4; 18(1) 19-21; 17(2) 39-41 |
| publishing of drug evaluations (editorial) 29(5) 120 |
| letter 30(2) 32-4 |
| quality use of generic drugs (editorial) 27(4) 80-1 |
| letters 28(2) 29-33; 27(6) 138-41 |
| regulation of advertising 27(5) 124-7 |
| retail pharmacy promotions (letters) 27(2) 28-33; 26(5) 99-102 |
| safety and withdrawal of COX inhibitors (editorial) 28(3) 54-5 |
| scheduling of drugs and poisons 20(1) 12-3 |
| pharmaceutical representatives 23(5) 97-9 |
| regulation and the internet 23(4) 73-4 |
| letter 23(6) 115-7 |
| starter packs and adverse effects 30(1) 14-16 |
| transparency of information about new drugs |
| editorial 28(4) 83-4 |
| transparency rating 30(1) 26-7; 28(4) 103 |
| letter 29(3) 59-62 |
| US Free Trade Agreement (editorial) 27(3) 54-5 |
| letter 27(5) 109-13 |
|
drug information
|
| AdWatch website review 27(3) 63 |
| Australian Medicines Handbook 21(3) 58-9; 20(1) 2-3 |
| book reviews 28(4) 93; 28(2) 41; 27(5) 113; 26(5) 110; 24(3) 55; 23(5) 105-6; 22(1) 19 |
| Australian Prescriber |
| 30th anniversary and history 28(5) 120-2 |
| letter 29(2) 32-5 |
| New drugs section editorial policy 25(5) 120 |
| common law duties of prescribers 19(1) 18-20 |
| consumer information on the internet 23(4) 73-4; 23(4) 75 |
| Consumer Medicine Information |
Home